{
  "id": 10442325,
  "title": "Vasomune Therapeutics Completes Enrollment of Phase 2a Study of Pegevongitide (AV-001) in Patients Hospitalized with Pneumonia/ARDS",
  "url": "https://urgent.news/2026/09/28/vasomune-therapeutics-completes-enrollment-of-phase-2a-study-of",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-28T12:20:35.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/vasomune-therapeutics-completes-enrollment-of-phase-2a-study-of-pegevongitide-av-001-in-patients-hospitalized-with-pneumonia-ards"
  },
  "original_language": "en",
  "account": null,
  "summary": "Enrollment milestone advances the FDA Fast Track-designated program toward data review and analysis TORONTO — Vasomune Therapeutics Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing medicines that target endotheliopathy and vascular leak, today announced the completion of patient enrollment in AV001-004 (NCT05123755), its randomized, double-blind, placebo-controlled Phase…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}